David Kim
CEO & Managing Director @ DigiTx Partners
San Francisco, United States
David Kim is a Series A investor at DigiTx Partners in San Francisco focused on Health Care and Medical Device. David J. Kim is based out of Brisbane, California and is the CEO & Managing Director of DigiTx Partners. David previously worked at Welldoc, Inc as a Board Observer. David J. Kim attended the Stanford University Graduate School of Business.
- Total investments:
- 19
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries David Kim invests in
Stages David Kim invests in
Countries David Kim invests in
Investment Focus
Industry
- Health Care 9 (47%)
- Medical Device 5 (26%)
- Artificial Intelligence 5 (26%)
- Medical 4 (21%)
- Software 4 (21%)
Stage
- Series A 8 (42%)
- Seed 4 (21%)
- Series B 3 (16%)
- Series C 1 (5%)
- Funding Round 1 (5%)
Country
- United States 13 (68%)
- Finland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
StrokeDx
|
StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor. | $5M / Seed / May 23, 2024 | |
CardioSignal
|
We develop groundbreaking solutions for the detection of heart diseases. CardioSignal is a mobile application and a certified medical device for the detection of atrial fibrillation. Originally an academic spinoff, the company’s patented technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product byPrecordior. www.cardiosignal.com | $10M / Series A / Jan 23, 2024 | |
Rune Labs
|
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $12M / Venture - Series Unknown / Jan 11, 2024 | |
Mightier
|
Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions. It is a bioresponsive program that harnesses the mind-body connection to build emotional regulation in its players. Its program of bioresponsive video games, developed at Boston Children's Hospital and Harvard Medical School, aims tohelp children with behavioral and emotional challenges learn how to harness emotions in daily life.Mightier was founded in 2016 and is headquartered in Boston, Massachusetts. | $17M / Series B / Dec 13, 2021 | |
|
Rune Labs
|
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $22.8M / Series A / Sep 16, 2021 | |
Nesos
|
Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University OfCalifornia, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists. | $16.5M / Dec 10, 2020 | |
|
Nesos
|
Nēsos develops and commercializes electrical field treatments for neurological disorders. It is critically supported by expert clinical and scientific collaborators from leading academic institutions, including Stanford, Vall d'Hebron, Harvard, Mount Sinai, Feinstein Institute, University Of California, San Diego (UCSD), and the University OfCalifornia, San Francisco (UCSF). It was co-founded by Konstantinos Alataris and other neuroscientists. | $16.5M / Dec 10, 2020 | |
Eko Health
|
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detectearlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com. | $65M / Series C / Nov 09, 2020 | |
|
Rune Labs
|
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future. The platform's software-as-a-service platform works with existing and emerging neuromodulation systems to manage complex therapies and get the most value out of available data. Their cloud-based software platform provides these therapy developersthe performance, scalability, and availability they need to run complex therapy algorithms across many patients, deliver precision medicine, and identify likely responders for clinical trials.Rune Labs was founded in 2018 and is headquartered in San Francisco, California. | $5M / Seed / Oct 26, 2020 | |
G-Tech Medical
|
G-Tech Medical is developing a wireless, wearable, disposable electrode patch to measure the electrical activity from the stomach, small intestine and colon. Most patients with abdominal pain, constipation, diarrhea or bloating have functional disorders that are not diagnosed with colonoscopies or CT scans. G-Tech's GutCheck patch will measuremotor activity and thus evaluate motility to allow physicians to better target the treatment. | Series A / May 21, 2020 | |
| See all 19 investments → | |||
Co-Investors
About DigiTx Partners
At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years. We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions. We look forward to supporting innovative companies that will make a difference in our healthcareecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction. DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.
DigiTx Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
David Kim
CEO & Managing Director
|
|||
Miraj Sanghvi
Partner
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Kim invest in?
David Kim invests primarily in Health Care, Medical Device and Artificial Intelligence startups, most often at Series A and Seed stage. Most of the 19 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David Kim last invest?
The most recent investment recorded for David Kim closed in May 2024. Shizune tracks 19 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
